Synlogic, Inc.
SYBX Healthcare Biotechnology
Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow SYBX
Synlogic, Inc. (SYBX) EV/Sales
As of 16 October 2026, Synlogic, Inc. (SYBX) trades at a EV/Sales of −0.2×. Over the past ten years it has ranged from −48.1× (November 2019) to 253× (September 2018); the current reading is higher than 55% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −0.6× | — |
| FY2023 | −5.5× | — |
| FY2022 | −20.7× | — |
| FY2021 | 3.1× | — |
| FY2020 | −1.5× | — |
| FY2019 | −18.6× | — |
| FY2018 | 17.9× | — |
| FY2017 | −5.7× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2024 | −3.4× | — |
| Dec 2023 | −5.5× | — |
| Sep 2023 | −28.3× | — |
| Jun 2023 | −16.2× | — |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −69.6× |
| SYBX Synlogic, Inc. | −0.2× |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| SKYE Skye Bioscience, Inc. compare | 12.9× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 24.2× |
| TCRT Alaunos Therapeutics, Inc. compare | 1,552× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)